Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Cardiac Multimodality Imaging in Hypertrophic Cardiomyopathy: What to Look for and When to Image

Author(s): Perry Wengrofsky, Yonatan Akivis and Inna Bukharovich*

Volume 19, Issue 5, 2023

Published on: 17 April, 2023

Article ID: e160323214676 Pages: 18

DOI: 10.2174/1573403X19666230316103117

Price: $65

Abstract

Hypertrophic cardiomyopathy (HCM), now recognized as a common cardiomyopathy of complex genomics and pathophysiology, is defined by the presence of left ventricular hypertrophy of various morphologies and severity, significant hemodynamic consequences, and diverse phenotypic, both structural and clinical, profiles. Advancements in cardiac multimodality imaging, including echocardiography, cardiac magnetic resonance imaging, and cardiac computed tomography, with and without angiography have greatly improved the diagnosis of HCM, and enable precise measurements of cardiac mass, volume, wall thickness, function, and physiology. Multimodality imaging provides comprehensive and complementary information and hasemerged as the bedrock for the diagnosis, clinical assessment, serial monitoring, and sudden cardiac death risk stratification of patients with HCM. This review highlights the role of cardiac multimodality imaging in the modern diagnosis and management of HCM.

Keywords: Hypertrophic cardiomyopathy, multimodality imaging, echocardiography, cardiac magnetic resonance imaging, cardiac computed tomography, cardiac death risk.

Graphical Abstract

[1]
Liew A, Vassiliou V, Cooper R, Raphael C. Hypertrophic cardiomyopathy-past, present and future. J Clin Med 2017; 6(12): 118.
[http://dx.doi.org/10.3390/jcm6120118] [PMID: 29231893]
[2]
Maron BJ, Maron MS. Reflections on six decades of hypertrophic cardiomyopathy from eugene braunwald. Am J Cardiol 2022; 172: 150-3.
[http://dx.doi.org/10.1016/j.amjcard.2022.01.031] [PMID: 35569882]
[3]
Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2022; 79(4): 372-89.
[http://dx.doi.org/10.1016/j.jacc.2021.12.002] [PMID: 35086660]
[4]
Monda E, Palmiero G, Lioncino M, et al. Multimodality imaging in cardiomyopathies with hypertrophic phenotypes. J Clin Med 2022; 11(3): 868.
[http://dx.doi.org/10.3390/jcm11030868] [PMID: 35160323]
[5]
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation 2020; 142(25): e558-631.
[http://dx.doi.org/10.1161/CIR.0000000000000937] [PMID: 33215931]
[6]
Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: An update from the American society of echocardiography, in collaboration with the American society of nuclear cardiology, the society for cardiovascular magnetic resonance, and the society of cardiovascular computed tomography. J Am Soc Echocardiogr 2022; 35(6): 533-69.
[http://dx.doi.org/10.1016/j.echo.2022.03.012] [PMID: 35659037]
[7]
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379(7): 655-68.
[http://dx.doi.org/10.1056/NEJMra1710575] [PMID: 30110588]
[8]
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy. Circ Res 2017; 121(7): 749-70.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.311059] [PMID: 28912181]
[9]
Neubauer S, Kolm P, Ho CY, et al. HCMR investigators distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry. J Am Coll Cardiol 2019; 74(19): 2333-45.
[http://dx.doi.org/10.1016/j.jacc.2019.08.1057] [PMID: 31699273]
[10]
Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Curr Opin Cardiol 2022; 37(1): 15-21.
[http://dx.doi.org/10.1097/HCO.0000000000000939] [PMID: 34636345]
[11]
Cheng Z, Fang T, Huang J, Guo Y, Alam M, Qian H. Hypertrophic cardiomyopathy: From phenotype and pathogenesis to treatment. Front Cardiovasc Med 2021; 8: 722340.
[http://dx.doi.org/10.3389/fcvm.2021.722340] [PMID: 34760939]
[12]
Dai Z, Aoki T, Fukumoto Y, Shimokawa H. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol 2012; 60(5): 416-21.
[http://dx.doi.org/10.1016/j.jjcc.2012.06.009] [PMID: 22867802]
[13]
Díez J, González A, Kovacic JC. Myocardial interstitial fibrosis in nonischemic heart disease, Part 3/4. J Am Coll Cardiol 2020; 75(17): 2204-18.
[http://dx.doi.org/10.1016/j.jacc.2020.03.019] [PMID: 32354386]
[14]
Wijnker PJM, Sequeira V, Kuster DWD, Velden J. Hypertrophic cardiomyopathy: A vicious cycle triggered by sarcomere mutations and secondary disease hits. Antioxid Redox Signal 2019; 31(4): 318-58.
[http://dx.doi.org/10.1089/ars.2017.7236] [PMID: 29490477]
[15]
Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: Past, present and future. Heart 2007; 94(10): 1276-81.
[http://dx.doi.org/10.1136/hrt.2008.154435] [PMID: 18653577]
[16]
Saito C, Minami Y, Haruki S, Arai K, Ashihara K, Hagiwara N. Prognostic relevance of a score for identifying diastolic dysfunction according to the 2016 American society of echocardiography/European association of cardiovascular imaging recommendations in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2022; 35(5): 469-76.
[http://dx.doi.org/10.1016/j.echo.2021.12.006] [PMID: 34933117]
[17]
Raphael CE, Cooper R, Parker KH, et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2016; 68(15): 1651-60.
[http://dx.doi.org/10.1016/j.jacc.2016.07.751] [PMID: 27712778]
[18]
Afonso LC, Bernal J, Bax JJ, Abraham TP. Echocardiography in hypertrophic cardiomyopathy: The role of conventional and emerging technologies. JACC Cardiovasc Imaging 2008; 1(6): 787-800.
[http://dx.doi.org/10.1016/j.jcmg.2008.09.002] [PMID: 19356516]
[19]
Rakowski H, Carasso S. Diastolic dysfunction and histopathology in hypertrophic cardiomyopathy: Is relaxation in disarray? J Am Soc Echocardiogr 2009; 22(12): 1335-7.
[http://dx.doi.org/10.1016/j.echo.2009.10.006] [PMID: 19944956]
[20]
Tower-Rader A, Mohananey D, To A, Lever HM, Popovic ZB, Desai MY. Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2019; 12(10): 1930-42.
[http://dx.doi.org/10.1016/j.jcmg.2018.07.016] [PMID: 30219395]
[21]
Sheikh N, Papadakis M, Schnell F, et al. Clinical profile of athletes with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2015; 8(7): e003454.
[http://dx.doi.org/10.1161/CIRCIMAGING.114.003454] [PMID: 26198026]
[22]
Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54(3): 201-11.
[http://dx.doi.org/10.1016/j.jacc.2009.02.075] [PMID: 19589432]
[23]
Kim EK, Lee SC, Hwang JW, et al. Differences in apical and non-apical types of hypertrophic cardiomyopathy: A prospective analysis of clinical, echocardiographic, and cardiac magnetic resonance findings and outcome from 350 patients. Eur Heart J Cardiovasc Imaging 2016; 17(6): 678-86.
[http://dx.doi.org/10.1093/ehjci/jev192] [PMID: 26245912]
[24]
Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2017; 10(7): e005372.
[http://dx.doi.org/10.1161/CIRCIMAGING.116.005372] [PMID: 28701526]
[25]
Inciardi RM, Galderisi M, Nistri S, Santoro C, Cicoira M, Rossi A. Echocardiographic advances in hypertrophic cardiomyopathy: Three-dimensional and strain imaging echocardiography. Echocardiography 2018; 35(5): 716-26.
[http://dx.doi.org/10.1111/echo.13878] [PMID: 29577429]
[26]
Venieri E, Aggeli C, Anastasakis A, Sambatakou H, Stefanadis C, Tousoulis D. Mitral valve in hypertrophic cardiomyopathy: A three-dimensional transesophageal study. Hellenic J Cardiol 2021; 62(1): 29-34.
[http://dx.doi.org/10.1016/j.hjc.2019.04.004] [PMID: 31002876]
[27]
Erden M, van Velzen HG, Menting ME, et al. Three-dimensional echocardiography for the assessment of left ventricular geometry and papillary muscle morphology in hypertrophic cardiomyopathy. J Ultrasound 2018; 21(1): 17-24.
[http://dx.doi.org/10.1007/s40477-017-0277-y] [PMID: 29374400]
[28]
Vainrib A, Massera D, Sherrid MV, et al. Three-dimensional imaging and dynamic modeling of systolic anterior motion of the mitral valve. J Am Soc Echocardiogr 2021; 34(1): 89-96.
[http://dx.doi.org/10.1016/j.echo.2020.08.019] [PMID: 33059963]
[29]
Lee DZJ, Chan RH, Montazeri M, et al. Left ventricular apical aneurysms in hypertrophic cardiomyopathy: Equivalent detection by magnetic resonance imaging and contrast echocardiography. J Am Soc Echocardiogr 2021; 34(12): 1262-72.
[http://dx.doi.org/10.1016/j.echo.2021.07.015] [PMID: 34375676]
[30]
Urbano-Moral JA, Gonzalez-Gonzalez AM, Maldonado G, et al. Contrast-enhanced echocardiographic measurement of left ventricular wall thickness in hypertrophic cardiomyopathy: Comparison with standard echocardiography and cardiac magnetic resonance. J Am Soc Echocardiogr 2020; 33(9): 1106-15.
[http://dx.doi.org/10.1016/j.echo.2020.04.009] [PMID: 32564979]
[31]
Wang Y, Zhang L, Liu J, et al. Automated three‐dimensional echocardiographic quantification for left ventricular volume and function in patients with hypertrophic cardiomyopathy. Echocardiography 2022; 39(5): 658-66.
[http://dx.doi.org/10.1111/echo.15322] [PMID: 35347747]
[32]
Chen Z, Li C, Li Y, et al. Layer‐specific strain echocardiography may reflect regional myocardial impairment in patients with hypertrophic cardiomyopathy. Cardiovasc Ultrasound 2021; 19(1): 15.
[http://dx.doi.org/10.1186/s12947-021-00244-3] [PMID: 33658038]
[33]
Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: Application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006; 47(6): 1175-81.
[http://dx.doi.org/10.1016/j.jacc.2005.10.061] [PMID: 16545649]
[34]
van Velzen HG, Schinkel AFL, van Grootel RWJ, et al. Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes. Neth Heart J 2019; 27(3): 117-26.
[http://dx.doi.org/10.1007/s12471-019-1226-5] [PMID: 30680638]
[35]
Finocchiaro G, Haddad F, Pavlovic A, et al. How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience. BMJ Open 2014; 4(6): e004814.
[http://dx.doi.org/10.1136/bmjopen-2014-004814] [PMID: 24928584]
[36]
Biagini E, Spirito P, Rocchi G, et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 2009; (104): (Suppl. 12)1727-31.
[http://dx.doi.org/10.1016/j.amjcard.2009.07.057]
[37]
Mitter SS, Shah SJ, Thomas JD. A test in context. J Am Coll Cardiol 2017; 69(11): 1451-64.
[http://dx.doi.org/10.1016/j.jacc.2016.12.037] [PMID: 28302294]
[38]
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr 2016; 29(4): 277-314.
[http://dx.doi.org/10.1016/j.echo.2016.01.011] [PMID: 27037982]
[39]
Kitaoka H, Kubo T, Hayashi K, et al. Tissue doppler imaging and prognosis in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2013; 14(6): 544-9.
[http://dx.doi.org/10.1093/ehjci/jes200] [PMID: 23060455]
[40]
Nagueh SF, McFalls J, Meyer D, et al. Tissue doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003; 108(4): 395-8.
[http://dx.doi.org/10.1161/01.CIR.0000084500.72232.8D] [PMID: 12860897]
[41]
Yang WI, Shim CY, Kim YJ, et al. Left atrial volume index: A predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22(12): 1338-43.
[http://dx.doi.org/10.1016/j.echo.2009.09.016] [PMID: 19879733]
[42]
Lu DY, Haileselassie B, Ventoulis I, et al. E/e′ ratio and outcome prediction in hypertrophic cardiomyopathy: the influence of outflow tract obstruction. Eur Heart J Cardiovasc Imaging 2018; 19(1): 101-7.
[http://dx.doi.org/10.1093/ehjci/jex134] [PMID: 28977350]
[43]
Singh A, Addetia K, Maffessanti F, Mor-Avi V, Lang RM. LA strain for categorization of LV diastolic dysfunction. JACC Cardiovasc Imag 2017; 10(7): 735-43.
[http://dx.doi.org/10.1016/j.jcmg.2016.08.014] [PMID: 28017389]
[44]
Jain V, Ghosh R, Gupta M, et al. Contemporary narrative review on left atrial strain mechanics in echocardiography: cardiomyopathy, valvular heart disease and beyond. Cardiovasc Diagn Ther 2021; 11(3): 924-38.
[http://dx.doi.org/10.21037/cdt-20-461] [PMID: 34295714]
[45]
Lee HJ, Kim HK, Rhee TM, et al. Left atrial reservoir strain-based left ventricular diastolic function grading and incident heart failure in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2022; 15(4): e013556.
[http://dx.doi.org/10.1161/CIRCIMAGING.121.013556] [PMID: 35439039]
[46]
Rakowski H, Carasso S. Quantifying diastolic function in hypertrophic cardiomyopathy: The ongoing search for the holy grail. Circulation 2007; 116(23): 2662-5.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.742395] [PMID: 18056537]
[47]
Chen S, Yuan J, Qiao S, Duan F, Zhang J, Wang H. Evaluation of left ventricular diastolic function by global strain rate imaging in patients with obstructive hypertrophic cardiomyopathy: A simultaneous speckle tracking echocardiography and cardiac catheterization study. Echocardiography 2014; 31(5): 615-22.
[http://dx.doi.org/10.1111/echo.12424] [PMID: 24219240]
[48]
Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27(16): 1933-41.
[http://dx.doi.org/10.1093/eurheartj/ehl041] [PMID: 16754630]
[49]
Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2016; 67(15): 1846-58.
[http://dx.doi.org/10.1016/j.jacc.2016.01.071] [PMID: 27081025]
[50]
Groarke JD, Galazka PZ, Cirino AL, et al. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging 2018; 19(10): 1109-16.
[http://dx.doi.org/10.1093/ehjci/jey095] [PMID: 30052928]
[51]
Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, Desai MY. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation. J Thorac Cardiovasc Surg 2010; 140(2): 317-24.
[http://dx.doi.org/10.1016/j.jtcvs.2009.10.045] [PMID: 20038476]
[52]
Teo EP, Teoh JG, Hung J. Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol 2015; 30(5): 475-82.
[http://dx.doi.org/10.1097/HCO.0000000000000200] [PMID: 26192489]
[53]
Kwon DH, Setser RM, Thamilarasan M, et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2007; 94(10): 1295-301.
[http://dx.doi.org/10.1136/hrt.2007.118018] [PMID: 17690158]
[54]
Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2000; 36(4): 1344-54.
[http://dx.doi.org/10.1016/S0735-1097(00)00830-5] [PMID: 11028493]
[55]
La Canna G, Scarfò I, Arendar I, Alati E, Caso I, Alfieri O. Phenotyping left ventricular obstruction with postprandial re-test echocardiography in hypertrophic cardiomyopathy. Am J Cardiol 2020; 125(11): 1688-93.
[http://dx.doi.org/10.1016/j.amjcard.2020.03.004] [PMID: 32279840]
[56]
Adams JC, Bois JP, Masaki M, et al. Postprandial hemodynamics in hypertrophic cardiomyopathy. Echocardiography 2015; 32(11): 1614-20.
[http://dx.doi.org/10.1111/echo.12951] [PMID: 26010128]
[57]
Jensen MK, Havndrup O, Pecini R, et al. Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Eur J Echocardiogr 2010; 11(9): 763-9.
[http://dx.doi.org/10.1093/ejechocard/jeq063] [PMID: 20472917]
[58]
Peng LT, Newman DB, Geske JB. Squat-to-stand provocation of dynamic left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: A case report. Eur Heart J Case Rep 2021; 5(1): ytaa450.
[http://dx.doi.org/10.1093/ehjcr/ytaa450] [PMID: 33644643]
[59]
Ayoub C, Geske JB, Larsen CM, Scott CG, Klarich KW, Pellikka PA. Comparison of valsalva maneuver, amyl nitrite, and exercise echocardiography to demonstrate latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol 2017; 120(12): 2265-71.
[http://dx.doi.org/10.1016/j.amjcard.2017.08.047] [PMID: 29054275]
[60]
Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Imag 2017; 10(11): 1374-86.
[http://dx.doi.org/10.1016/j.jcmg.2017.07.016] [PMID: 29122139]
[61]
Schwammenthal E, Nakatani S, He S, et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: Mismatch of posterior to anterior leaflet length and mobility. Circulation 1998; 98(9): 856-65.
[http://dx.doi.org/10.1161/01.CIR.98.9.856] [PMID: 9738640]
[62]
Gilbert BW, Pollick C, Adelman AG, Wigle ED. Hypertrophic cardiomyopathy: Subclassification by M mode echocardiography. Am J Cardiol 1980; 45(4): 861-72.
[http://dx.doi.org/10.1016/0002-9149(80)90133-2] [PMID: 6444777]
[63]
Elsheshtawy MO, Mahmoud AN, Abdelghany M, Suen IH, Sadiq A, Shani J. Left ventricular aneurysms in hypertrophic cardiomyopathy with midventricular obstruction: A systematic review of literature. Pacing Clin Electrophysiol 2018; 41(7): 854-65.
[http://dx.doi.org/10.1111/pace.13380] [PMID: 29786883]
[64]
Hughes RK, Knott KD, Malcolmson J, et al. Apical hypertrophic cardiomyopathy: The variant less known. J Am Heart Assoc 2020; 9(5): e015294.
[http://dx.doi.org/10.1161/JAHA.119.015294] [PMID: 32106746]
[65]
Strachinaru M, Huurman R, Bowen DJ, Schinkel AFL, Hirsch A, Michels M. Relation between early diastolic mid-ventricular flow and elastic forces indicating aneurysm formation in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2022; 35(8): 846-856.e2.
[http://dx.doi.org/10.1016/j.echo.2022.04.010] [PMID: 35489541]
[66]
Po JRF, Kim B, Aslam F, et al. Doppler systolic signal void in hypertrophic cardiomyopathy: Apical aneurysm and severe obstruction without elevated intraventricular velocities. J Am Soc Echocardiogr 2015; 28(12): 1462-73.
[http://dx.doi.org/10.1016/j.echo.2015.08.015] [PMID: 26422555]
[67]
Salerno M, Sharif B, Arheden H, et al. Recent advances in cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2017; 10(6): e003951.
[http://dx.doi.org/10.1161/CIRCIMAGING.116.003951] [PMID: 28611116]
[68]
Sivalokanathan S. The role of cardiovascular magnetic resonance imaging in the evaluation of hypertrophic cardiomyopathy. Diagnostics 2022; 12(2): 314.
[http://dx.doi.org/10.3390/diagnostics12020314] [PMID: 35204405]
[69]
To ACY, Dhillon A, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy. JACC Cardiovasc Imag 2011; 4(10): 1123-37.
[http://dx.doi.org/10.1016/j.jcmg.2011.06.022] [PMID: 21999873]
[70]
Chen X, Pan J, Shu J, et al. Prognostic value of regional strain by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy. Quant Imag Med Surg 2022; 12(1): 627-41.
[http://dx.doi.org/10.21037/qims-21-42] [PMID: 34993107]
[71]
Pu C, Fei J, Lv S, et al. Global circumferential strain by cardiac magnetic resonance tissue tracking associated with ventricular arrhythmias in hypertrophic cardiomyopathy patients. Front Cardiovasc Med 2021; 8: 670361.
[http://dx.doi.org/10.3389/fcvm.2021.670361] [PMID: 34124201]
[72]
Rajiah P, Fulton NL, Bolen M. Magnetic resonance imaging of the papillary muscles of the left ventricle: Normal anatomy, variants, and abnormalities. Insights Imag 2019; 10(1): 83.
[http://dx.doi.org/10.1186/s13244-019-0761-3] [PMID: 31428880]
[73]
Gupta AN, Avery R, Soulat G, et al. Direct mitral regurgitation quantification in hypertrophic cardiomyopathy using 4D flow CMR jet tracking: Evaluation in comparison to conventional CMR. J Cardiovasc Magn Reson 2021; 23(1): 138.
[http://dx.doi.org/10.1186/s12968-021-00828-y] [PMID: 34865629]
[74]
Soler R, Méndez C, Rodríguez E, Barriales R, Ochoa JP, Monserrat L. Phenotypes of hypertrophic cardiomyopathy. An illustrative review of MRI findings. Insights Imag 2018; 9(6): 1007-20.
[http://dx.doi.org/10.1007/s13244-018-0656-8] [PMID: 30350182]
[75]
Hinojar R, Varma N, Child N, et al. T1 mapping in discrimination of hypertrophic phenotypes: Hypertensive heart disease and hypertrophic cardiomyopathy. Circ Cardiovasc Imag 2015; 8(12): e003285.
[http://dx.doi.org/10.1161/CIRCIMAGING.115.003285] [PMID: 26659373]
[76]
Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: A comprehensive review. J Cardiovasc Magn Reson 2017; 18(1): 89.
[http://dx.doi.org/10.1186/s12968-016-0308-4] [PMID: 27899132]
[77]
Wong TC. Cardiovascular magnetic resonance imaging of myocardial interstitial expansion in hypertrophic cardiomyopathy. Curr Cardiovasc Imaging Rep 2014; 7(5): 9267.
[http://dx.doi.org/10.1007/s12410-014-9267-z] [PMID: 24719675]
[78]
Chen S, Huang L, Zhang Q, Wang J, Chen Y. T2-weighted cardiac magnetic resonance image and myocardial biomarker in hypertrophic cardiomyopathy. Medicine 2020; 99(23): e20134.
[http://dx.doi.org/10.1097/MD.0000000000020134] [PMID: 32501969]
[79]
Gastl M, Gruner C, Labucay K, et al. Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy. Open Heart 2020; 7(1): e001152.
[http://dx.doi.org/10.1136/openhrt-2019-001152] [PMID: 32201584]
[80]
Rowin EJ, Maron BJ, Maron MS. The hypertrophic cardiomyopathy phenotype viewed through the prism of multimodality imaging. JACC Cardiovasc Imag 2020; 13(9): 2002-16.
[http://dx.doi.org/10.1016/j.jcmg.2019.09.020] [PMID: 31864978]
[81]
Conte E, Mushtaq S, Muscogiuri G, et al. The potential role of cardiac CT in the evaluation of patients with known or suspected cardiomyopathy: From traditional indications to novel clinical applications. Front Cardiovasc Med 2021; 8: 709124.
[http://dx.doi.org/10.3389/fcvm.2021.709124] [PMID: 34595219]
[82]
Langer C, Lutz M, Eden M, et al. Hypertrophic cardiomyopathy in cardiac CT: A validation study on the detection of intramyocardial fibrosis in consecutive patients. Int J Cardiovasc Imaging 2014; 30(3): 659-67.
[http://dx.doi.org/10.1007/s10554-013-0358-8] [PMID: 24449335]
[83]
Di Cori A, Zucchelli G, Faggioni L, et al. Role of pre-procedural CT imaging on catheter ablation in patients with atrial fibrillation: Procedural outcomes and radiological exposure. J Interv Card Electrophysiol 2021; 60(3): 477-84.
[http://dx.doi.org/10.1007/s10840-020-00764-4] [PMID: 32405889]
[84]
Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. Eur Heart J 2009; 30(13): 1627-34.
[http://dx.doi.org/10.1093/eurheartj/ehp121] [PMID: 19406869]
[85]
Sellers SL, Fonte TA, Grover R, et al. Hypertrophic cardiomyopathy (HCM): New insights into Coronary artery remodelling and ischemia from FFRCT. J Cardiovasc Comput Tomogr 2018; 12(6): 467-71.
[http://dx.doi.org/10.1016/j.jcct.2018.08.002] [PMID: 30139668]
[86]
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35(39): 2733-79.
[http://dx.doi.org/10.1093/eurheartj/ehu284] [PMID: 25173338]

Rights & Permissions Print Cite
Article Metrics
28
3
© 2024 Bentham Science Publishers | Privacy Policy